Skip to main content
Clinical Trials/NCT04602611
NCT04602611
Completed
N/A

A Randomized, Controlled Prospective Trial Evaluating The Impact Of A Nurse Navigation Program on Patients With Gastrointestinal Cancers Undergoing Oncological Treatment

Wake Forest University Health Sciences1 site in 1 country228 target enrollmentNovember 3, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Gastrointestinal Cancer
Sponsor
Wake Forest University Health Sciences
Enrollment
228
Locations
1
Primary Endpoint
Annualized Count of Acute Care Visits
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to learn about the impact of the Oncology Nurse Navigation program on the frequency of Emergency Department, urgent care visits and inpatient hospital admissions; and overall survival rate at 6 months. The investigators aim to understand if prompt and effective coordination of care provided by Oncology Nurse Navigation (ONN) service will reduce the number of avoidable, unplanned ED visits and hospitalizations, as well as adding measurable value to cancer care, and improve patient overall survival.

Detailed Description

A randomized controlled prospective trial evaluating the effectiveness of a nurse navigation program for gastrointestinal cancer patients undergoing oncological treatment. Upon accrual, patients will be randomized 1:1 to receive standard of care plus ONN service (n = 107) or standard of care only (without ONN service; n = 107). Patients in both arms will be assessed for acute care utilization and overall survival (OS) rate at 6 months. Anticipated accrual period will be 30 months.

Registry
clinicaltrials.gov
Start Date
November 3, 2020
End Date
August 10, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Annualized Count of Acute Care Visits

Time Frame: From the date of randomization until subject discontinued the intervention, assessed up to 34 months

The annualized count of acute care visits, where acute care visits included all unplanned inpatient admissions, emergency room encounters, and/or urgent care visits, was calculated for each subject as the total number of acute care visits normalized to an annual basis.

Proportion of Participants Surviving at 6 Months

Time Frame: From the date of randomization to death or 6 months

The proportion of participants surviving at 6 months was calculated for each treatment arm. Six-month overall survival was determined for each subject as a binary variable indicating whether or not the subject was alive at 6 months after study enrollment. Failure occurred if the subject died from any cause within 6 months of study enrollment. The proportions were compared between the arms.

Secondary Outcomes

  • Proportion of Participants Surviving at 12 Months(From the date of randomization up until 12 months)
  • Hospital Length of Stay(From the date of randomization until subject discontinued the intervention, assessed up to 34 months)
  • Time From Hospice Referral to Death for Participants Referred to Hospice(From the date of hospice referral to death or last follow-up, assessed over 7 months.)
  • Total Number of 30-day Readmissions(From the date of randomization until subject discontinued the intervention, assessed up to 34 months)
  • Proportion of Participants Referred to Supportive Care Services(From the date of randomization until subject discontinued the intervention, assessed up to 34 months)
  • Proportions of Missed Visits of All Scheduled Visits From 0% to 100%.(From the date of randomization until subject discontinued the intervention, assessed up to 34 months)
  • Average Score of Subject Satisfaction as Assessed by an Adaptation of the EORTC PATSAT C33(From the date of randomization up until 14 weeks)

Study Sites (1)

Loading locations...

Similar Trials